March 21, 2022
News
January 4, 2022
Artiva Biotherapeutics Strengthens Leadership Team with the Appointment of Christopher Horan as Chief Technical Operations Officer
October 21, 2021
Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting CAR-NK Cell Therapy, at SITC 36th Annual Meeting
September 30, 2021
Artiva Biotherapeutics Demonstrates Its Commitment to Corporate Social Responsibility by Joining Pledge 1% Movement
August 12, 2021
Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply
May 19, 2021
Artiva Biotherapeutics Appoints Two New Independent Members to Its Board of Directors
April 6, 2021
Artiva Biotherapeutics Appoints Michael E. Faerm as Chief Financial Officer
February 26, 2021
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
January 28, 2021
Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies
January 5, 2021